Opinion

Video

New Data from AANEM 2024 in Generalized Myasthenia Gravis

Key Takeaways

  • Gene therapy advancements for inherited neuromuscular disorders were a significant focus, highlighting potential transformative impacts on treatment paradigms.
  • Novel pharmacological interventions targeting specific molecular pathways showed promise, indicating a shift towards more targeted therapeutic approaches.
SHOW MORE

Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.

Video content above is prompted by the following:

  • Please share other interesting/practice-impacting data that were presented at AANEM 2024.
    • What other emerging treatments are you excited about?
Related Videos
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.